Septerna (NASDAQ:SEPN) Trading Down 5.5% – Here’s What Happened

Septerna, Inc. (NASDAQ:SEPN)’s share price fell 5.5% on Friday . The stock traded as low as $22.97 and last traded at $23.4720. 38,317 shares were traded during mid-day trading, a decline of 87% from the average session volume of 287,771 shares. The stock had previously closed at $24.83.

Wall Street Analyst Weigh In

Several analysts recently commented on SEPN shares. Truist Financial increased their price objective on shares of Septerna from $34.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. HC Wainwright increased their price objective on shares of Septerna from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Zacks Research raised shares of Septerna from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Wall Street Zen downgraded shares of Septerna from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, JonesTrading started coverage on shares of Septerna in a research report on Tuesday, December 23rd. They set a “buy” rating and a $43.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Septerna currently has a consensus rating of “Moderate Buy” and an average price target of $43.14.

Septerna Trading Down 7.0%

The firm has a 50 day simple moving average of $26.21 and a 200 day simple moving average of $24.88. The firm has a market capitalization of $1.04 billion, a PE ratio of -20.80 and a beta of 3.50.

Septerna (NASDAQ:SEPN) last issued its earnings results on Monday, March 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.01). Septerna had a negative net margin of 106.37% and a negative return on equity of 15.85%. The business had revenue of $24.12 million for the quarter, compared to analysts’ expectations of $20.44 million. Research analysts forecast that Septerna, Inc. will post -7.11 earnings per share for the current year.

Insider Transactions at Septerna

In other news, insider Samira Shaikhly sold 70,453 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $28.10, for a total transaction of $1,979,729.30. Following the sale, the insider owned 793 shares of the company’s stock, valued at $22,283.30. This trade represents a 98.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Elizabeth Bhatt sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $28.97, for a total transaction of $115,880.00. Following the sale, the chief operating officer directly owned 174,209 shares in the company, valued at approximately $5,046,834.73. The trade was a 2.24% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 4.30% of the company’s stock.

Institutional Trading of Septerna

Institutional investors have recently made changes to their positions in the stock. Group One Trading LLC boosted its stake in shares of Septerna by 111.8% in the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock worth $26,000 after buying an additional 8,955 shares during the last quarter. Global Retirement Partners LLC purchased a new position in shares of Septerna in the 4th quarter worth $35,000. Russell Investments Group Ltd. purchased a new position in shares of Septerna in the 3rd quarter worth $36,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Septerna in the 4th quarter worth $53,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Septerna in the 4th quarter worth $61,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.